Drug Trial Radar · NCT04265209
[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor
Last checked: Nov 20, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
152
Actual
Start
Dec 1, 2021
Primary completion
Aug 2, 2024
Study completion Aug 2, 2024
Sponsor
- Lead sponsor
- GE HealthcareIndustry
- Sponsor type
- Industry
- First posted
- Feb 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (outcomes assessor)
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 35 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Clinical study to demonstrate an at least equivalent performance of a new PET molecular Imaging radiopharmaceutical named \[18F\] LBT-999 in brain imaging compared to the SPECT reference method named \[123I\]-FP-CIT to establish the differential diagnosis between Parkinson's Disease and Essential Tremor.
Conditions
- Parkinson Disease
- Essential Tremor
Interventions
SPECTDrug
\[123I\]-FP-CIT SPECT imaging procedure
PETDrug
\[18F\] LBT-999 PET imaging procedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity and specificity by visual analysisTime frame: The independent review committee will analyse the PET and SPECT images blindly. These analyses will be done by batch of 25 patients. Outcome will be assessed at the end of the study, an average of 2 years after first patient in.
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Hôpital Avicenne
Bobigny, France
CHU Bordeaux
Bordeaux, France
Centre Jean PERRIN / Hôpital Gabriel Montpied (CHU)
Clermont-Ferrand, France
Hôpital Henri Mondor
Créteil, France
CLCC Georges-François Leclerc C.G.F.L
Dijon, France
Hôpital Roger Salengro (CHRU de Lille)
Lille, France
Hospices Civils de Lyon
Lyon, France
CHU La Timone
Marseille, France
Hôpital Brabois / Hôpital Central (CHRU Nancy)
Nancy, France
Hôpital Laennec (CHU Nantes)
Nantes, France
Centre Hospitalier Universitaire de Nîmes
Nîmes, France
CHU La Pitié Salpêtrière
Paris, France
Centre Eugène Marquis / CHU Pontchaillou
Rennes, France
Institut de cancérologie Strasbourg Europe
Strasbourg, France
Hôpital Pierre Paul Riquet - Purpan (CHU)
Toulouse, France
CHRU Hôpital Bretonneau
Tours, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.